Daily non-political popular news in brief.

Hopkins scientists uncover cause of antipsychotic drug weight gain

02-12-2007 · EurekAlert!

Johns Hopkins brain scientists have hit on how and why some powerful drugs used for treating mental illnesses cause patients to gain so much weight that they often develop life-threatening complications such as diabetes and heart disease.

Keywords: hopkins, scientists, uncover, cause, antipsychotic, drug, weight, gain, hopkin, scientist

« Previous | Next »

Similar news on "Hopkins scientists uncover cause of antipsychotic drug weight gain":

'Exercise pill' switches on gene that tells cells to burn fat
04-29-2007 · EurekAlert!
By giving ordinary adult mice a drug -- a synthetic designed to mimic fat -- scientists are now able to chemically switch on PPAR-d, the master regulator that controls the ability of cells to burn fat. Even when the mice are not active, turning on the chemical switch activates the same fat-burning process that occurs during exercise. The resulting shift in energy balance (calories in, calories burned) makes the mice resistant to weight gain on a high fat diet.
Similar news · Read more »
How antipsychotic drugs can cause weight gain
03-03-2007 · Science News Online
A study of mice has identified a biological mechanism by which medications called atypical antipsychotics cause people to gain weight.
Similar news · Read more »
Diabetes medication and lifestyle changes can help treat weight gain induced by antipsychotic drugs
01-08-2008 · EurekAlert!
Lifestyle intervention and the drug metformin are both effective against antipsychotic-induced weight gain, and treatment is most effective when the two therapies are combined, according to a study in the Jan. 9/16 issue of JAMA.
Similar news · Read more »
Studies look at how genes affect antipsychotic drug response
11-09-2006 · EurekAlert!
Researchers at the University of Illinois at Chicago College of Pharmacy are attempting to discover how genes determine how well an antipsychotic medication works in adults and children and the side effects it will cause.
Similar news · Read more »
Advance in understanding of blood pressure gene could lead to new treatments
02-04-2007 · EurekAlert!
Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
Similar news · Read more »
Drug treatment slows macular vision loss in diabetics
12-15-2006 · EurekAlert!
A drug commonly used to slow the loss of central vision has shown promise in stemming a common precursor of blindness in diabetics, which involves the same central light-sensitive area of retina, Johns Hopkins Wilmer Eye Institute scientists report.
Similar news · Read more »
Uncovering the molecular basis of obesity
06-05-2007 · EurekAlert!
Why does the same diet make some of us gain more weight than others? The answer could be a molecule called Bsx, as scientists from the European Molecular Biology Laboratory (EMBL), the German Institute for Nutrition (DIFE), Potsdam, and the University of Cincinnati report in the current issue of Cell Metabolism. Bsx is the molecular link between spontaneous physical activity and food intake.
Similar news · Read more »
'Knocking out' cell receptor may help block fat deposits in tissues, prevent weight gain
10-25-2007 · EurekAlert!
University of Cincinnati pathologists have identified a new molecular target that one day may help scientists develop drugs to reduce fat transport to adipocytes in the body and prevent obesity and related disorders, like diabetes.
Similar news · Read more »
How does soy promote weight loss? University of Illinois scientist finds another clue
05-01-2007 · EurekAlert!
Research shows that when soy consumption goes up, weight goes down. A new University of Illinois study may help scientists understand exactly how that weight loss happens.
Similar news · Read more »
New alzheimer's drug shows promise in clinical trial
11-02-2006 · EurekAlert!
The only drugs currently available for Alzheimer's patients are those that alleviate symptoms, but a team of scientists led by Paul Aisen, MD, director of the Memory Disorders program at Georgetown University Medical Center, is testing a new class of drugs that actually target the molecule believed to cause the disease.
Similar news · Read more »